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Bayesian decision theoretic two-stage
design in phase II clinical trials with
survival endpoint
Lili Zhao,a*† Jeremy M. G. Taylorb and Scott M. Schuetzec
In this paper, we consider two-stage designs with failure-time endpoints in single-arm phase II trials. We pro-
pose designs in which stopping rules are constructed by comparing the Bayes risk of stopping at stage I with the
expected Bayes risk of continuing to stage II using both the observed data in stage I and the predicted survival
data in stage II. Terminal decision rules are constructed by comparing the posterior expected loss of a rejection
decision versus an acceptance decision. Simple threshold loss functions are applied to time-to-event data modeled
either parametrically or nonparametrically, and the cost parameters in the loss structure are calibrated to obtain
desired type I error and power. We ran simulation studies to evaluate design properties including types I and
II errors, probability of early stopping, expected sample size, and expected trial duration and compared them
with the Simon two-stage designs and a design, which is an extension of the Simon’s designs with time-to-event
endpoints. An example based on a recently conducted phase II sarcoma trial illustrates the method. Copyright
© 2012 John Wiley & Sons, Ltd.
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1. Introduction
In phase II cancer clinical trials, the standard approach consists of a single-arm design where a single
binary endpoint is compared with a specified target value. The sample sizes are typically small, maybe
3070 patients. Improvements to the study could be made by increasing the sample size, using random-
ization and using an endpoint that is more informative than a binary one. Limitations on the available
number of patients frequently limits power for a randomized study. Our focus in this paper will be on
enhancing the trials using nonbinary endpoints. We will consider designs with failure-time endpoints,
measuring time until some event, such as a device-related complication, disease progression, relapse,
or death. Progression-free survival (PFS) is increasingly used as an endpoint for cancer clinical trials,
and a recent review suggests that PFS is being utilized more commonly and may predict for greater suc-
cess in the phase III setting [1]. Using PFS as an endpoint in single-arm studies does raise some issues
concerning the possibility of bias in the comparison with the historical control group [2–4]. Although
there is always the possibility of differences in the populations and in methods for assessing the endpoint
between the trial and the control group, when using PFS, a consistent surveillance strategy for assessing
progression is also needed.
A single-arm phase II trial is typically designed to accrue patients in two stages [5–7], with the Simon
design being very popular. It will stop at stage I if a preset level of futility has been demonstrated, thereby
reducing the number of patients exposed to an ineffective therapy. Similar to classical phase II studies, a
study based on a time-to-event endpoint (such as median PFS or PFS rate at a specific clinical landmark
point, t0) will be deemed a success if there is sufficient statistical evidence to conclude that the endpoint
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exceeds, at a clinically relevant level, that of a relevant historical control. Many statistical designs are
based on the probability that the patient survives to specific time t0 without suffering the event. The
most severe problem created by this approach is that a patient has to be followed-up for t0 time to ensure
that event has not occurred, and waiting until all patients in stage I complete the follow-up of t0 may
cause long recruitment suspension especially when t0 is large. The impact of study suspension on accrual
momentum and timeliness of the studies completion is often negative. A number of authors have formu-
lated underlying statistical models and interim decision rules directly in terms of time-to-event variables
to overcome this problem. Herndon [8] proposed a frequentist ad hoc approach to conducting two-stage
phase II studies to avoid study suspension. Case and Morgan [9] proposed frequentist two-stage phase
II designs using the estimator developed by Lin et al. [10] to minimize the expected sample size or
expected total study length (ETSL) under H0. Huang et al. [11] modified their approach to protect type I
error rate and improve robustness of the design. These designs [9, 11] are essentially an extension of the
Simon designs with failure time endpoints using nonparametric statistics.
Researchers developed several Bayesian approaches to continuously monitor survival endpoints.
Follman and Albert [12] used a Dirichlet process prior for the probabilities of the event on a large set of
potential discretized event times. They compute an approximate posterior distribution that is a mixture
of Dirichlet processes by using a data augmentation algorithm. Rosner [13] took a similar approach but
used Gibbs sampling to generate posteriors. Cheung and Thall [14] constructed futility monitoring rules
on the basis of an approximate posterior through a weighted average of beta distributions for one or
more event times in phase II trials. These approaches incorporate the censored data into the posterior
estimation in a nonparametric fashion. Thall et al. [15] developed model-based approaches to monitor
time-to-event endpoints, assuming exponentially distributed failure times with an inverse gamma prior
on the mean. They also examined the robustness of the method by assuming that the survival data follows
a generalized gamma distribution. In the aforementioned Bayesian designs (e.g., [14, 15]), decisions are
made using the posterior distribution of the clinically relevant survival endpoints, and the futility mon-
itoring rule is typically based on P.pE > pS C ıjdata/ < pL . Thus, the trial is stopped early if the
posterior probability that pE (such as median survival or survival rate at a specific time point of the
experimental treatment) exceeds a clinical meaningful threshold (ı) over the traditional treatment pS
by less than a prespecified cutoff, pL. The pL can be calibrated by simulations to obtain good trial
properties such as probability of early termination, type I error, and power [16].
The property of Bayesian procedures to accumulate evidence based on updated data is very attractive
in clinical trial designs. However, at the end of stage I, most investigators are interested in knowing
what is the probability that the study would yield a significant result in favor of the new treatment if
the study were to be continued to stage II, given what has been observed to date. Lachin [17] reviewed
many frequentist approaches that construct stopping rules on the basis of an assessment of this idea
using (predictive) conditional power. Pepe and Anderson [18] presented expressions for the types I and
II error probabilities for use with time-to-event endpoints assuming current trends continue for survival
data. Berry [19] is also a strong advocate for the use of predictive probabilities in making decisions.
However, the aforementioned approaches (frequentist or Bayesian) use only the predictive distribution
to make interim decisions. In this paper, we will weight the evidence for stopping or continuing on the
basis of posterior and predictive distributions. Once the trial is stopped, the posterior distribution is used
for making terminal decisions.
In the literature, researchers have developed decision-based Bayesian methods for binary endpoints
[20–24]. Zhao and Woodworth [25] proposed a decision-based Bayesian approach for continually mon-
itoring survival endpoints in single-arm phase II trials with medical devices, but the time-to-event data
was assumed to be exponentially distributed.
In practice, the decision theoretic clinical trial designs remain relatively uncommon. The main rea-
sons for this lack of application are fundamental concerns with the decision theoretic setup and practical
difficulty of specifying a good loss function [26]. In decision-theoretic approaches, costs need to be
specified, and in most situations, it is very hard to relate the costs to tangible quantities. Our strategy to
make this approach feasible is to treat the cost parameters, defined in a simple loss structure, as tuning
parameters, which are calibrated to achieve desired operating characteristics such as type I error and
power. This approach alleviate concerns about difficulties in specifying the loss function, and as we will
show, the properties of the decision theoretic designs appear to be very attractive.
Section 2 presents the general framework and methodology. Section 3 contains simulation studies to
evaluate the properties of the proposed methods and compares the results to two frequentist designs.
Section 4 contains results from a phase II sarcoma trial. Section 5 is the concluding discussion.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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2. Method
The primary endpoint is a time-to-event outcome at some clinically meaningful landmark point t0; such
as 6 months or 1 year from the start of the treatment. Let S.t0/ be the survival rate at t0. Similar to most
other designs with a binary endpoint of tumor response, decisions are made based on two hypotheses H0:
S.t0/ 6 p1 that the true survival rate at t0 is less than some uninteresting level p1 and H1: S.t0/ > p2
that the survival rate is at least some desirable target level p2.













where‚ are the parameters that determine the distribution f .t/ and D is the observed data, which include
survival times, t D .t1; t2; : : : ; tn/ and corresponding indicators of censoring, ı D .ı1; ı2; : : : ; ın/.
In this paper, we have chosen a very simple loss function as specified in Table I. There are two pos-
sible wrong decisions: (1) false rejection (type I error) and (2) false acceptance (type II error). c2 is the
penalty you are willing to pay for a false rejection decision over a false acceptance decision. In deci-
sion theory, c2 could be a function of the sample size or could differ from stage I to stage II. In this
paper, not to overcomplicate things, we consider c2 as fixed and treat c2 as a tuning parameter to control
type I error and power. A rejection decision will be made if the posterior expected loss of making a
rejection decision (e.g., c2P.S.t0/ <D p1jD/) is less than that of making an acceptance decision (e.g.,
P.S.t0/ >D p2jD/), and an acceptance decision will be made otherwise. The higher the c2, the less
likely we are going to reject H0 to avoid the high penalty of a false rejection decision. But before we
decide to stop and make a terminal decision (reject or accept H0), we should compare the risk of stop-
ping at stage I to the ‘expected’ risk if the trial will be continued to stage II. The (posterior) Bayes risk of
immediate stopping at stage I, denoted by 0.1/; is defined as the minimum of the (posterior) expected
losses under two decisions,
0.
1/DminfP.S.t0/> p2jD1/; c2P.S.t0/6 p1jD1/g
whereD1 are the observed data up to stage I; 1 is the posterior distribution of S.t0/ given the observed
data up to stage I, denoted by f .S.t0/jD1/.




D ED2jD1 ŒminfP.S.t0/> p2jD2/; c2P.S.t0/6 p1jD2/gC c3 (2)
Table I. Threshold loss structure.
True status of the treatment
Noninferior
Inferior Neither Superior
.S.t0/6 p1/ .p1 < S.t0/ < p2/ .S.t0/> p2/
Accept H0 0 0 1
Decision
Reject H0 c2 0 0
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where 2 is the posterior distribution of S.t0/ given the observed data up to stage II, denoted by
f .S.t0/jD2/. c3 is the cost of running the trial to the final stage, which could be a function of the
sample size or study length in stage II. In this paper, c3 is also fixed to control the probability of stopping
at the end of stage I. The higher the c3, the more likely the trial will be halted at stage I to avoid the high
cost of continuing the trial. ED2jD1 Œ0.








2;l/ when B is large: (3)
where 2;l is f .S.t0/jD2;l/ andD2;l (l D 1; 2; : : : ; B) are the random samples of potential datasetsD2
generated given D1.
In brief, the decision rule is as follows:
 At the end of stage I
- if 0.1/6 c.1/, then stop and





- else if 0.1/ > c.1/, then continue to stage II
 At the end of stage II, stop and





The aforementioned decision rules are attractive for two reasons. First, the terminal decision rule is
constructed using the ratio of two posterior probabilities under two hypotheses (e.g., similar to posterior
odds). Second, the decision to ‘stop’ or ‘continue’ is the result of weighting the evidence between the
observed data and the data that will be observed if the trial would continue.
Once the posterior distribution of‚ is known, the distribution of S.t0/; as a function of‚, can be com-
puted using Monte Carlo methods. Therefore, it is easy to calculate the posterior probabilities under the
two hypotheses. It is, however, much harder to calculate the Bayes risk of continuation, which involves
the posterior predictive distribution of D2 given D1 in the presence of censoring. In the following sec-
tion, we derive algorithms to estimateED2jD1 Œ0.
2/ for exponential failure time distributions, Weibull
distributions, and time-to-event data that do not follow any parametric distribution.
2.1. Method assuming exponential distribution
Assume the time-to-event data follows an exponential distribution, f .t/ D et for t > 0; and the
primary endpoint S.t0/ is defined as S.t0/D et0 .




, where f k is the total number
of failures and ek is the total exposure time up to stage k (k D 1; 2). These are sufficient statistics to
estimate . D then can be simplified to D1 D .f 1; e1/ and D2 D .f 2; e2/: For mathematical conve-
nience, we use the conjugate prior for  such that   .˛0; ˇ0/. Then, the posterior distribution is
easily determined to be a Gamma distribution, f .jDk/ .˛0C f k; ˇ0C ek/:
Given the data up to stage I (D1), we can simulate the patients’ survival data in stage II. The number
of patients in stage II (denoted by N2) has two parts: (1) the number of event-free patients that have
not reached the final study point at the end of stage I; and (2) the number of new patients recruited in
stage II. Because of the ‘lack of memory” property of the exponential distribution, those patients that are
event free at the end of stage I are conditionally exchangeable with patients who are recruited in stage
II, and their survival times in stage II will also be distributed as an exponential distribution with rate
  .˛0 C f
1; ˇ0 C e
1/. Zhao and Woodworth [25] defined the algorithm to obtain samples of D2
given D1.
2.2. Method assuming Weibull distribution
The Weibull distribution, denoted by W.˛; /, is f .t/D ˛t˛1et˛ for t > 0; ˛ > 0, and  > 0. Let
‚D .˛; / and the primary endpoint is S.t0/D et
˛
0 :
In this case, Dk D .tk; ık/; k D 1; 2. tk includes all survival times for patients enrolled up to stage
k, and ık are the corresponding censoring indicators. Unlike the exponential distribution, there are no
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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simple sufficient statistics and no simple posterior distributions for ˛ and  . MCMC methods will be
used to estimate these two parameters.
This Weibull model can be expressed as a log-linear model as log tiD C 	
i [27], where  D





´i /; where ´i D
yi 
	
If we assign  a uniform prior and for 	 the usual noninformative prior proportional to 1=	 , then the
posterior density is given by
f .; 	 jDk//
1
	
L.; 	 jDk/; k D 1; 2 (4)
Metropolis–Hasting algorithms can easily be applied to estimate  and 	 .
Given the data up to stage I (D1 D .t1; ı1/), survival times for patients enrolled in stage II will be
generated from a Weibull distribution with the updated‚ from stage I. For any patient i that is censored
at the end of stage I and has not reached the final study point, the probability that the patient will survive
additional time xi is expressed as
S.xi /D P.t > t
1






















where ˛l and l are from the l th MCMC iteration. Then, xi;l ; l D 1; : : : ; B are random samples from
the posterior predictive distribution of the remaining survival time of patient i in stage II.
Let t2
i;l
D minft1i C xi;l ;Mig, ı
2
i;l
D 1 if t2
i;l
<Mi and ı2i;l D 0 otherwise, where Mi is the maximum
follow-up for patient i defined from the enrollment to the final study time point. We repeat this process
for all patients (i D 1; : : : ; N2) in stage II, and together with the observed survival data of patients that
had event, we obtain D2;l . Then, D2;1; : : : ;D2;B form a random sample from the posterior predictive
distribution of f .D2jD1/:
Similar methods can be developed assuming Gamma or log-normal distributions.
2.3. Grouped-data method
In practice, interval-censored survival data is common in medical settings where the patient’s disease
status is evaluated periodically by tests such as magnetic resonance imaging or computed axial tomog-
raphy scan. The actual time of any patients disease progression is not available, rather, it is only known
whether progression occurred during each time interval between successive examinations. To account
for this type of interval censoring, we propose a nonparametric method in this section, which handles
the interval-censored data for various time-to-event data distributions.
Given the data up to stage I (D1), we construct a finite partition of the time axis, 0 < s1 < s2 <
   < sJ ; with sJ D t0. Thus, we have the J disjoint intervals .0; s1; .s1; s2; : : : ; .sJ1; sJ ; and
Ij D .sj1; sj . The value of sj .j D 1; : : : ; J /, in the interval-censored case, should be determined by
the intended gap between two consecutive scheduled appointments. For example, the scheduled appoint-
ment is every 2 months for the first half year, then the intervals can be set up as s1 D 2; s2 D 4; s3 D 6;
and J D 3. For studies where the evaluation is more frequent, the value of J would be much larger.
The observed data D is assumed to be available as grouped within these intervals such that Dk D
.Rkj ;Dkj W j D 1; 2; : : : ; J /; where Rkj is the risk set and Dkj is the failure set of the j th interval Ij up
to stage k. Let hj denote the increment in the cumulative baseline hazard in the j th interval, that is,
hj DH0.sj /H0.sj1/; j D 1; 2; : : : ; J (6)
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where rkj and d
k
j are the number of subjects in the sets Rki and Dkj up to stage k, respectively.
The Gamma process is used as a prior for the cumulative baseline hazard function H0.t/ [28]
such that
H0  GP.0H; 0/; (8)
whereH.t/ is an increasing function withH.0/D 0: H is assumed to be a Weibull distribution with
hyperparameter 0 and 0; such that H.t/ D 0t0 : 0 is a positive scalar quantifying the degree of
prior confidence in H.t/: If 0 D 1, this simplifies as an exponential distribution with rate 0.




With the likelihood and priors set up as that previously discussed, we can write the posterior



















where hj denote the h vector without j th component. Plugging in the form for Gkj from Equation (7),
we have














Survival times are approximated by piecewise constant hazard survival model. Thus, the memoryless
property of the exponential distribution holds in each interval Ij ; j D 1; 2; : : : ; J . Given data observed
up to stage I (D1), survival times for patients in stage II (i D 1; : : : ; N2) will be generated on the basis
of the updated h1; : : : ; hJ . For any patient i that is censored in interval Ij at the end of stage I and
has not reached the final study point, the remaining survival time, xi;j;l ; will first be generated from
an exponential distribution with rate hj
sjsj1
, then moving from left to right along the time line until
the event occurs or the final study time point is reached, which will result in generated survival times,
xi;j;l ; xi;jC1;l ; : : : in intervals Ij ; IjC1; : : : ; respectively. Let ti;j;l D minfxi;j;l ; .minfsj ;Mig  t1i /gI
if ti;j;l D sj  t1i (no event occurred in Ij and the final study point has not been reached), we will
move to IjC1. If no event occurred in IjC1 and Mi > sjC1; then ti;jC1;l D sjC1  sj . Finally,
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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t2
i;l
D t1i C ti;j;l C ti;jC1;l C : : : : For patients enrolled in stage II, this process starts at I1. We repeat
this process for all patients (i D 1; : : : ; N2) in stage II to obtain a random sample from the posterior
predictive distribution of f .D2jD1/.
We note that with the use of a large number of intervals, this grouped-data method can be viewed
as a nonparametric method for general distributions that would be applicable even if the data were not
interval censored.
3. Simulation studies
In this section, we ran simulations to investigate properties of the proposed designs (Bayes designs)
including type I error, power, probability of early stopping (PET), expected sample size, and ETSL under
both null and alternative hypotheses. In the simulation setup, we assumed the landmark time point, t0,
to be 6 months; we took the interim analysis 1 day before the first patient of stage II was enrolled such
that there is no trial suspension and defined the final study point as 6 months after the enrollment of the
last patient; the maximum follow-up per patient is 12 months; we sampled the patient arrival time from
a Poisson distribution with a rate of 0.1 so that one patient arrives an average of every 10 days.
In Simon’s designs, we dichotomize the survival time into a binary variable I.t 6 t0). With such
designs, the trial will continue immediately to stage II once the number of successes reaches the thresh-
old rather than waiting for all enrolled patients to complete the follow-up and stops immediately if there
is no hope that the threshold will be met. For example, consider the situation where three successes of
10 is needed for the trial to continue to stage II. If only one success is observed for the first nine patients
that had completed the follow-up, the trial should stop even though the last patient has not completed the
follow-up because we would observe at most two successes in this case. For the Simon designs, we will
consider both the MiniMax and the optimal designs. To be comparable with the Simon’s designs, which
only allow early stopping for futility, the stopping rule in the Bayes design is modified as




This ‘Stop only for futility’ rule is used throughout the simulations unless specified otherwise.
As well as comparing with the Simon designs, we will also make comparisons with the method
described in [11]. This method prevents trial suspension by using Nelson–Aalen estimates of the sur-
vival calculated at different calendar times to account for the information available from those with
partial follow-up. We implemented this method using the R program OptimPhase2.
3.1. Effect of the cost parameters
In this simple loss structure, cost parameter c2 controls the trade-off between types I and II errors and
cost parameter c3 controls the PET. In this section, we investigated the effect of c2 and c3 while fixing the
other. We calculated total sample size (nD 47) and the sample size in stage I (n1 D 24) from the Simon
MiniMax design by restricting type I error to be 0.05 and type II error to be 0:15 with the two decision
thresholds p1 D 0:1 and p2 D 0:25: We generated survival data from an exponential distribution with
rate  logS.t0/
t0
;where S.t0/ D 0:1 or 0:25: We used an uninformative Gamma prior distribution, with
mean 0.0001 and rate 0.0001, for .
Figure 1 demonstrates the effect of c3 when c2 is fixed to be 5. The highest c3 (e.g., c3 D 0:1) gives
the highest PET across different S.t0), and c3 of 0.03 provides similar PET as the MiniMax design. In
Figure 2, c3 is fixed to be 0.03. The highest c2 (e.g., c2 D 10) has the lowest probability of rejecting the
H0; resulting in the lowest power at S.t0/ D 0:25 as well as the lowest type I error at S.t0/ D 0:1. We
found that the choice of c2 D 3 and c3 D 0:03 gives type I error of 0.03 and power of 0.9. To obtain
approximately type I error of 0.05 and power of approximately 0.85, to match the MiniMax design, we
reduced the sample size by 32% to nD 32 given c2 D 3 and c3 D 0:03. With this sample size, we investi-
gated the operating characteristics of trials with different design parameters such as different hypotheses
(p1 and p2), different patient accrual rates, different timing of the interim look, a stopping rule that
allows stopping for both efficacy and futility, and different prespecified values for types I and II errors.
Without loss of generality, we used the exponential method for data that are exponentially distributed.
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Figure 1. (a) Probability of rejecting H0 for various S.t0/, given three choices of c3 with c2 fixed to be 5, and
(b) the corresponding probability of early stopping when p1 is true for various S.t0/, given three choices of c3
with c2 fixed to be 5 (on the basis of 1000 trial simulations and 1000 (B D 1000) simulations in calculating the
expected Bayes risk of continuation).







































Figure 2. (a) Probability of rejecting H0 for various S.t0/, given three choices of c2 with c3 fixed to be 0.03, and
(b) the corresponding probability of early stopping when p1 is true for various S.t0/, given three choices of c2
with c3 fixed to be 0.03 (on the basis of 1000 trial simulations and 1000 (B D 1000) simulations in calculating
the expected Bayes risk of continuation).
3.2. Trial properties with different design parameters
3.2.1. Trials with different hypotheses. We base the results shown in Table II on 5000 simulations of
the same trial and 1000 (B D 1000) simulations in calculating the Bayes risk of continuation. With
c2 D 3 and c3 D 0:03; all the studied cases have type I error of approximately 0.05 and power of
approximately 0.85 using about 30% less total sample size than the MiniMax design. The Bayes designs
significantly shorten the average trial duration with much smaller expected sample sizes, compared with
other designs. For example, in the first scenario, it shortens the total study length by 4 months if S.t0/
is 0.1 and by 7 months if S.t0/ is 0.25, compared with the MiniMax design. The savings in sample size
are even more under the alternative hypothesis because of the dramatically reduced total sample size
and seamless enrollment. The PET is low in the Bayes design under the null hypothesis. This, nonethe-
less, does not result in longer trial duration and larger expected sample size because of the dramatically
reduced total sample size. And increasing n1 would increase the PET as will be presented in the next
section. The outperformance of the Bayes designs over the Simon’s designs is mainly due to making use
of more information with the time-to-event data rather than the dichotomized data in Simon’s designs.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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Table II. Operating characteristics of the exponential method for trials with different hypotheses given type
I error of approximately 0.05 and power of approximately 0.85, with c2 D 3 and c3 D 0:03, based on
exponentially distributed survival data.
Under H0 Under H1
Design n.n1/ a PET EN ETSLb PET EN ETSL
0:10vs0:25
MiniMaxc 47(24) 0.57 34 17 0.04 46 23
Optimald 50(20) 0.68 30 15 0.09 47 24
H-ETSLe 52(33) 0.62 40 16 0.09 50 22
Bayes 32(16) 0.34 27 13 0.04 31 16
0:2vs0:4
MiniMax 37(17) 0.55 26 15 0.05 36 21
Optimal 51(17) 0.76 25 13 0.12 47 25
H-ETSL 49(31) 0.67 37 14 0.08 48 21
Bayes 26(13) 0.25 23 12 0.03 26 14
0:3vs0:45
MiniMax 76(35) 0.51 55 24 0.04 75 33
Optimal 86(29) 0.64 49 22 0.09 81 36
H-ETSL 98(48) 0.68 64 23 0.08 94 37
Bayes 54(27) 0.38 44 18 0.04 53 23
0:5vs0:7
MiniMax 44(22) 0.60 31 16 0.04 43 24
Optimal 52(17) 0.67 28 15 0.09 49 26
H-ETSL 66(37) 0.69 46 17 0.06 64 27
Bayes 30(15) 0.23 27 13 0.03 30 16
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
an in the Bayes designs is about 70% of the sample size calculated from the corresponding MiniMax design, and n1 is
half of the total sample size.
bThe unit of ETSL is months.
cMiniMax design is targeted at minimizing the maximum sample size under the null hypothesis.
dOptimal design is targeted at minimizing the expected sample size under the null hypothesis.
eH-ETSL is targeted at minimizing the ETSL. The sample size is calculated using the OptimDes function in the Optim-
Phase2 package in R while fixing the power 0.85 and type I error 0.05. The operating characteristics are obtained with
the SimDes function in the OptimPhase2 package.
On the contrary, the H-ETSL design, although it successfully avoids trial suspension, will not necessarily
reduce the trial duration.
The optimal designs give smaller expected sample size and shorter averaged trial duration than the
MiniMax designs under the null hypotheses (the opposite is true under the alternatives). We will use the
optimal design for the comparisons for the rest of the article.
3.2.2. Trials with the interim look taken at a different time point. As illustrated in Table III, larger
n1 gives higher PET under the null hypothesis. Increasing n1 from 16 to 24 further reduces the
trial duration by 1 month. This fact suggests that interim analysis may be performed after we accu-
mulate more data information (larger n1 or longer follow-up), which will provide us with more
evidence to terminate the trial early if the null hypothesis is true, thereby increasing the PET and
shortening the trial duration especially when the patient actual is fast. In contrast with the Bayes
designs, smaller n1 in Simon’s designs gives larger PET when the optimal design is compared with
the MiniMax design (Table II). This reflects a fundamental problem in frequentist designs based on
hypothesis testing, in which the hypotheses are set up to collect evidence to prove the treatment is
promising (i.e., reject the H0), which leads to the tendency to declare the treatment bad with smaller
sample sizes.
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Table III. Operating characteristics of the exponential method for hypothesis of 0.1 vs 0.25, with the interim
look taken at different time points given type I error of approximately 0.05 and power of approximately 0.85,
with c2 D 3 and c3 D 0:03, based on exponentially distributed survival data.
Under H0 Under H1
n.n1/ PET EN ETSL PET EN ETSL
32(8) 0.12 29 15 0.03 31 16
32(16) 0.34 27 13 0.04 31 16
32(24) 0.61 27 12 0.06 31 16
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
3.2.3. Trials with stopping for both efficacy and futility. Stopping for both futility and efficacy is nat-
urally embedded within the decision-theoretic framework. As demonstrated in Table IV, type I error
and power are increased slightly by allowing stopping for efficacy as well as for futility. Increasing
c2 (such as c2 D 4) would lower the probability of rejection (that is, the type I error and power) by
approximately 2% .
3.2.4. Trials with different interpatient arrival times. As presented in Figure 3, the Bayes design has
the smallest averaged trial duration for a wide range of accrual rates under both the null and alternative
hypotheses. The H-ETSL design only shows some benefit over the optimal design under the alternative
hypothesis when the accrual rate is very fast.
3.2.5. Trials with different type I error and power. Different clinical trials may have different require-
ments for the type I error and power. In cancer trials, other choices may be as follows: (1) type I error
of 5% with power of 80% or (2) type I error of 10% with power of 90 %. With 70 % of the total sample
size calculated from the MiniMax design, we found, as shown in Table V, that c2 D 4 and c3 D 0:03
give type I error of approximately 0.05 and power of approximately 0.80, and c2 D 1 and c3 D 0:02 give
type I error of approximately 0.1 and power of approximately 0.90.
3.3. Simulation using the Weibull method
Thus far, we have assumed that survival data is exponentially distributed. If the event rates are not
constant, however, a more complex distribution is required. In this section, we applied the Weibull
method for data generated from Weibull distributions with various shape parameters (denoted by ˛)
given S.t0/ D 0:1 or 0:25. We base the results in Table VI on 500 simulated trials and 250 (B D 250)
simulations to calculate the expected Bayes risk of continuation. With c2 D 3 and c3 D 0:03; the type I
error is approximately 0.05 and power is approximately 0.85, regardless of different shape parameters.
Table IV. Operating characteristics of the exponential method with stopping for both futility and efficacy, for
different hypotheses with c2 D 3 and c3 D 0:03, based on exponentially distributed survival data.
Under H0 Under H1
n.n1/ Type I error PET EN ETSL Power PET EN ETSL
0:10vs0:25
32(16) 0.07 0.36 26 13 0.86 0.31 27 13
0:2vs0:4
26(13) 0.08 0.29 22 12 0.85 0.23 23 12
0:3vs0:45
54(27) 0.07 0.39 43 18 0.85 0.31 46 19
0:5vs:0:7
30(15) 0.08 0.27 26 13 0.88 0.24 26 13
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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Figure 3. (a) Expected trial duration when S.t0/ D 0:1 for various interpatient arrival times; and (b) expected
trial duration when S.t0/D 0:25 for various interpatient arrival times.
Table V. Operating characteristics of the exponential method, for different hypotheses with different type I
error and power, based on exponentially distributed survival data.
Under H0 Under H1
Design n.n1/ Type I error PET EN ETSL Power PET EN ETSL
c2 D 4 and c3 D 0:03
0:1vs0:25
Optimal 43(18) 0.05 0.73 25 13 0.80 0.14 40 22
Bayes 28(14) 0.05 0.29 24 12 0.80 0.04 27 15
0:2vs0:4
Optimal 43(13) 0.05 0.75 20 12 0.80 0.16 38 22
Bayes 24(12) 0.05 0.24 21 12 0.79 0.03 24 14
0:3vs0:45
Optimal 82(30) 0.05 0.58 52 23 0.80 0.07 79 35
Bayes 46(23) 0.05 0.33 39 17 0.82 0.05 45 21
0:5vs0:7
Optimal 43(15) 0.05 0.70 24 13 0.80 0.13 39 23
Bayes 26(13) 0.04 0.19 24 13 0.81 0.02 26 14
c2 D 1 and c3 D 0:02
0:1vs0:25
Optimal 50(21) 0.10 0.67 31 15 0.90 0.07 48 24
Bayes 28(14) 0.09 0.24 25 13 0.87 0.04 27 15
0:2vs0:4
Optimal 37(17) 0.10 0.56 26 15 0.90 0.05 36 21
Bayes 26(13) 0.09 0.19 23 13 0.90 0.03 26 14
0:3vs0:45
Optimal 81(27) 0.10 0.59 51 23 0.90 0.07 78 34
Bayes 50(25) 0.11 0.28 43 19 0.90 0.04 49 22
0:5vs0:7
Optimal 45(21) 0.10 0.66 29 15 0.90 0.07 43 24
Bayes 28(14) 0.10 0.15 26 14 0.90 0.02 28 15
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
1814
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
L. ZHAO, J. M. G. TAYLOR AND S. M. SCHUETZE
Table VI. Operating characteristics of the Weibull method for hypothesis of 0.1 vs 0.25, given type I error
of approximately 0.05 and power of approximately 0.85 except that BayesII gives power approximately 0.87
and type I error of approximately 0.07, with c2 D 3 and c3 D 0:03, based on Weibull distributed survival
data.
Under H0 Under H1
Design n.n1/ PET EN ETSL PET EN ETSL
˛ D 0:5
Optimal 50(20) 0.68 30 14 0.09 47 24
H-ETSL 53(31) 0.66 39 15 0.09 51 22
Bayes 32(16) 0.36 26 13 0.04 31 16
Bayes 32(24) 0.58 27 12 0.03 32 16
BayesII 32(16) 0.38 26 12 0.34 27 13
˛ D 1
Optimal 50(20) 0.68 30 15 0.09 47 24
H-ETSL 52(33) 0.62 41 16 0.09 50 22
Bayes 32(16) 0.23 28 14 0.03 32 16
Bayes 32(24) 0.43 29 13 0.03 32 16
BayesII 32(16) 0.22 29 14 0.25 28 14
˛ D 1:5
Optimal 50(20) 0.68 30 15 0.09 47 24
H-ETSL 52(34) 0.62 41 16 0.09 50 22
Bayes 32(16) 0.15 30 15 0.03 32 16
Bayes 32(24) 0.38 29 13 0.02 32 16
BayesII 32(16) 0.19 29 15 0.18 29 15
˛ D 2
Optimal 50(20) 0.67 30 16 0.09 47 24
H-ETSL 52(34) 0.61 41 16 0.09 50 22
Bayes 32(16) 0.14 30 15 0.03 32 16
Bayes 32(24) 0.33 29 14 0.03 32 16
BayesII 32(16) 0.19 29 14 0.19 29 14
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
Again, the Weibull method significantly shortens the trial duration with only 70% of the sample size
from the MiniMax design. The PET decreases as the median failure time increases (as measured by ˛)
because more events (evidence) are observed with smaller median failure times, which leads to shorter
trial duration and smaller expected sample size.
Table VI also suggests that waiting longer (larger n1) to make the interim decision could result in
higher PET and shorter trial duration under the null hypothesis (compare n1 D 16 versus n1 D 24).
3.3.1. Robustness with the Weibull method. We examined the robustness of the Weibull method for data
generated from log-normal and Gamma distributions. As we can see from Table VII, the Weibull method
is very robust in the cases studied.
3.4. Simulation using the grouped-data method
If time-to-event data can be assumed to follow a parametric distribution, the Weibull method could
be performed because of its robustness presented in the last section. In this section, we evaluate a
design for trials for which the majority of the events are observed at the scheduled tumor assessment
time points. The grouped-data method was applied to survival data generated from various distributions
such as Weibull, log-normal, and Gamma distributions. The time points of the grid were chosen to be
0 < 2 < 4 < 6 under the assumption that the appointment is scheduled every 2 months. Prior parameters
of 0D0:1 and D0:014 (01) imply that a priori, P(S.t0/ < 0:1/D 0:16 and P(S.t0/ > 0:25/D 0:8.
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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Table VII. Operating characteristics of the Weibull method for hypothesis of 0.1 vs 0.25, with c2 D 3 and
c3 D 0:03, based on Weibull, Gamma, and log-normal distributed survival data.
Under H0 Under H1
Design n.n1/ Type I error PET EN ETSL Power PET EN ETSL
LN (,2)
Optimal 50(20) 0.05 0.68 30 14 0.85 0.09 47 23
Bayes 32(24) 0.05 0.73 26 10 0.80 0.10 31 16
LN (,1)
Optimal 50(20) 0.05 0.67 30 15 0.85 0.02 47 24
Bayes 32(24) 0.05 0.64 27 11 0.86 0.06 32 16
G.1; b/
Optimal 50(20) 0.05 0.68 30 15 0.85 0.09 47 24
Bayes 32(24) 0.05 0.41 29 13 0.85 0.04 32 16
G.2; b/
Optimal 50(20) 0.05 0.68 30 15 0.85 0.09 47 24
Bayes 32(24) 0.05 0.45 28 13 0.82 0.05 32 16
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
But this prior distribution of S.t0/ is flat, so that the influence of the prior on the posterior distribution is
small. We increased n1 from 24 to 30 to gain more information at the end of stage I.
With the results shown in Table VIII with 500 repeated trials and 250 (B D 250) simulations for
the expected Bayes risk of continuation, the grouped-data method shortens the trial duration only under
the alternative hypotheses because of the seamless recruitment. With the same total sample size as in the
MiniMax design, the significantly lower PET in the Bayes design (even based on six more patients than
in the MiniMax design) results in longer trial duration under the null hypothesis. With slower accrual or
longer follow-up per patient, the trial could have higher PET. We also found that allowing stopping for
both efficacy and futility increased the type I error to about 10%–15% (results not shown). Therefore, we
would suggest that a trial only be allowed to stop for futility when the grouped-data method is applied.
4. Application of the methods to a sarcoma clinical trial
The primary objective of this trial is to evaluate the 6-month PFS rate in patients with advanced sarcoma
treated with oral cyclophosphamide and sirolimus (OCR). The trial was originally designed using the
Simon MiniMax design. Patients who are progression free and alive at 6 months following the initia-
tion of study treatment will be considered a success. A 25% or greater 6-month PFS rate from OCR
treatment would be considered as showing potential activity of the combination, thus worthy of further
study. A 10% or less 6-month PFS rate from OCR is considered uninteresting for additional study. With
a type I error rate of 5%, the study of 47 evaluable patients will provide 85% power to detect an effective
treatment. Tumor imaging will be performed every 2 months until tumor progression or until the patient
completes 12 cycles of treatment. Each cycle is 28 days long. According to the MiniMax design, 24
patients will be enrolled in stage I. If three or more patients are alive and free from sarcoma progression
6 months after enrollment, an additional 23 patients will be enrolled in the second stage of the study. If
nine or more of the 47 patients are alive and free of progression 6 months after enrollment, the proposed
treatment will be declared as having anti-sarcoma activity worthy of further study. The trial is now closed
for accrual, and the trial was paused for about 2 months until three patients reached 6 months follow-up
and were free of progression and thereafter continued to stage II. The trial declared the OCR treatment
as promising after nine patients were progression free after 6 months in stage II.
If we could design the trial using the Bayes design, we would choose c2 D 3 and c3 D 0:03 for type
I error of 0.05 and power of 0.85 as specified in the MiniMax design. Then, we assume that patients
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Table VIII. Operating characteristics of the grouped-data method for hypothesis of 0.1 vs 0.25, given type
I error of approximately 0.05 and power of approximately 0.85, based on Weibull, Gamma, and log-normal
distributed survival data.
Under H0 Under H1
Design n.n1/ PET EN ETSL PET EN ETSL
W(0.5, )
Optimal 50(20) 0.68 30 14 0.09 47 24
Bayes 47(30) 0.48 39 16 0.03 47 21
W(1.5, )
Optimal 50(20) 0.68 30 15 0.09 47 24
Bayes 47(30) 0.25 43 19 0.02 47 21
LN (,2)
Optimal 50(20) 0.68 30 14 0.09 47 23
Bayes 47(30) 0.53 38 16 0.03 46 21
LN (,1)
Optimal 50(20) 0.67 30 15 0.09 47 24
Bayes 47(30) 0.32 42 18 0.02 47 21
G.1; b/
Optimal 50(20) 0.68 30 15 0.09 47 24
Bayes 47(30) 0.33 41 18 0.03 47 21
G.2; b/
Optimal 50(20) 0.68 30 15 0.09 47 24
Bayes 47(30) 0.24 43 19 0.02 47 22
PET, probability of early stopping; EN, expected sample size; ETSL, expected total study length.
Table IX. Oral cyclophosphamide and sirolimus trial data.
Time to progression/death (days)
Stage I (D1) 103; 112; 212C; 210C; 112; 111; 56; 59; 111; 31;
142C; 110; 61; 133C; 133C; 93C; 51; 87C; 56;
74C; 67C; 53C; 31C; 11
Stage II (D2) 103; 112; 225; 360C; 112; 111; 56; 59; 111; 31;
162; 110; 61; 223; 360C; 225; 51; 253; 56;
107; 219; 140; 55; 11; 112; 113; 53; 112; 56;
184C; 180C; 56; 57; 54; 61; 28; 56; 56; 49; 100C; 95;
85C; 52; 62; 65C; 56; 42C
in stage II are enrolled 2 months earlier than their true enrollment dates such that there is no trial sus-
pension at the end of stage I. The end of stage II is defined when nine patients reach the time t0 and
are free of progression under this hypothetical enrollment schedule. In contrast to the Simon’s designs,
which require waiting for one more event from the nine patients that are event free and have not been
followed-up for 6 months, the Bayes design will make the interim decision on the basis of the data D1
in Table IX.
In this trial, although the design should lead to interval censored data, the variation of patient schedul-
ing, death without confirmed progression, and clinical progression that triggers an earlier detection of
the progression, in our view, justify using a parametric distribution for the event time data. Because the
mean estimate of ˛ is about 1.6 based on the data D1, the Weibull method was used. We then tried the
Weibull method using 68% of the sample size as in the MiniMax design (nD32) with n1D24. In the first
Copyright © 2012 John Wiley & Sons, Ltd. Statist. Med. 2012, 31 1804–1820
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Table X. Expected losses and decisions at two stages.
Stage I Stage II
n.n1/ Action ELoss 0 c Decision ELoss Decision
Weibull
47.24/ Accept 0.64 0.08 0.04 Continue 0.38 Reject
Reject 0.08 0.02
32.24/ Accept 0.64 0.08 0.05 Continue 0.75 Reject
Reject 0.08 0.01
Grouped data
47.30/ Accept 0.65 0.02 0.03 Continue 0.40 Reject
Reject 0.02 0.02
design, the posterior expected loss of a rejection and an acceptance decision are 0.08 and 0.64, respec-
tively (see Table X). The smaller of these two is 0.08, which is the Bayes risk of immediate stopping.
Because it is larger than the expected Bayes risk of continuation (c D 0:04), the trial is continued to the
second stage. At the end of the trial, the posterior expected loss of a rejection decision is smaller (0.02
vs 0.38). Therefore, we reject the H0. In the first two designs, 0 is the same because D1 is the same in
both designs, whereas c is smaller in the first design because more information (less risk) is expected
if we would enroll more patients in the second stage given the same c3.
We note that using the grouped-data method with the same time points of grids and priors as specified
in the simulation studies, we would also reject H0.
All the three designs give the same conclusion as the MiniMax design that the OCR is effective, but
the Bayes designs have shorter trial duration.
5. Discussion
There are three reasons for the use of decision-based Bayesian approach in designing clinical trials with
interim looks. First, it is natural to make ‘stop’ or ‘continue’ decisions on the basis of the risk of ‘stop’
and ‘continue’ if the trial will continue to the final stage. Once we decide to stop, the terminal decision is
based on the observed data alone (with noninformative priors). Second, the terminal decision rule (reject
or accept) is constructed by weighting the evidence of two hypotheses. Third, calibrating the two cost
parameters to obtain desired type I error and power makes the decision-based approaches feasible in
clinical trial designs, and the robustness of the properties of the designs to cost parameters, irrespective
of patient accrual rates, hypotheses, timing of the interim look, and three proposed methods, makes the
design very appealing.
Compared with the commonly used Simon’s designs, the decision-based Bayesian designs have the
following advantages: (1) no need to pause the trial at the end of stage I to wait for all the patients to
reach the landmark point; (2) significantly shorter average trial duration and much smaller sample size;
(3) a flexible design that could easily add early stopping for efficacy as well as for futility; and (4) rea-
sonable design properties (such as PET), which are based on weight of evidence in the data rather than
awkward frequentist hypothesis tests.
In addition, the proposed methods can be easily adapted to randomized trials with survival endpoints.
In such trials, the ‘difference’ in the survival rate between treatment and control groups will be moni-
tored. This ‘difference’ could be represented as a parameter in the accelerated failure time model or Cox
regression model. The terminal decision rule and stopping rule will be constructed using the posterior
and predictive distribution of this parameter.
In this paper, we did not include patients that are lost to follow-up or dropout before reaching the land-
mark point. This information can be easily incorporated into the estimation methods for the Bayesian
model [25]. In contrast, designs that use binary endpoints do not have a natural way to incorporate this
partial information.
We used quite noninformative prior to reflect limited experience with the experimental regimen under
considerations. In certain special situations in which more experience with experimental treatment is
available, other priors could be used.
Assuming exponential distributions, trials can be designed with many stages because of the simple
sufficient statistics. The grid method using backward induction makes the computation time increase
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linearly with the number of stages. However, the Weibull and grouped-data methods are practically lim-
ited to two stages mainly because there are not a small number of sufficient statistics [30, 31]. For these
two methods, Bayes risk was calculated in a forward fashion, for which the computation time increase
exponentially with the number of stages, which makes adding one more interim look computationally
infeasible although theoretically possible.
In summary, Bayesian decision-based approaches are feasible in designing clinical trials with appeal-
ing properties. As more and more experience accumulates with the application of this approach in real
trials, it may be possible to design the trials by directly specifying the costs rather than treating them as
tuning parameters.
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